|Day Low/High||49.99 / 50.85|
|52 Wk Low/High||42.48 / 63.69|
"Bull markets are born on pessimism, grow on skepticism, mature on optimism and die on euphoria." -- Sir John Templeton DuPont (still on my Best Ideas List) and 3M accounted for 110% of today's gain in the Dow Jones Industrial Average. It was the ...
These may be uncharted waters, but they're not necessarily expensive.
Icahn may have a tough time finding interest in this behemoth.
TheStreet's Jim Cramer comments on Wednesday's most talked about stocks.
Here are 5 things you must know before the market opens Wednesday.
Toll Brothers TOL says the average price of a home it built declined, due to the cost of building materials.
Every single market indicator I look at is overbought. But it's likely that shorts and underperformers are buoying stocks. Some are at the most overbought in decades. The bond market is clearly not as sanguine on economic growth/corporate profi...
Jana Partners are placing three members on Tiffany's board.
I started the day with a discussion of the new administration's policies and why I believe there are headwinds to their passage over the next few months or quarters. I covered last evening's Procter & Gamble short for a profit. "For Traders Only."...
Jim Cramer compares Allergan's growth to other pharma stocks.
Two industries should largely be avoided under this administration: pharma and retail.
"The Dow hit 20,000 and I am proud of it ... Now we have to go up, up, up. It's gone up a lot since I won. We hit a number that has never been hit before. So, I am very honored." --President Donald Trump, ABC interview Wednesday night If the market ...
Bristol-Myers Squibb needs to reorganize itself in what is now a challenging environment, says Jim Cramer.
I am reluctant to call this a breakout, and am willing to sit back and wait.
The market continues to be in rally mode as everyone watches the presidential inauguration ceremonies. Biotech is not participating in the rally. Bristol Myers-Squibb is one reason the sector is not participating, as its key oncology drug Opdivo wil...
Jim Cramer looks at Bristol-Myers Squibb's Opdivo setback.
Bristol-Myers Squibb suffers a setback in immunotherapy treatment for newly diagnosed lung cancer.
I had my most active day of the year trading. It was also my most profitable. Regardless of one's market view, I continue to see more opportunities on the trading side vs. the investing side in the months ahead. I started the day with a story re...
Jana Partners' Barry Rosenstein recently acquired a large stake in Bristol-Myers.
Wall Street secured gains again by late afternoon Wednesday in unpredictable trading following President-elect Donald Trump's first press conference since July.
Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.